Dimethyl fumarate reduces inflammatory responses in experimental colitis

Journal of Crohn's and Colitis

Volumn 10, Issue 4, 2016, Pages 472-483

  Casili, Giovanna ^a   Cordaro, Marika ^a   Impellizzeri, Daniela ^a   Bruschetta, Giuseppe ^a   Paterniti, Irene ^a   Cuzzocrea, Salvatore ^a,b   Esposito, Emanuela ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dimethyl fumarate; DNBS; Inflammatory bowel diseases

Indexed keywords

DINITROBENZENE SULPHURIC ACID; FUMARIC ACID DIMETHYL ESTER; GELATINASE A; GELATINASE B; HYDROGEN PEROXIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; MANGANESE SUPEROXIDE DISMUTASE; MYELOPEROXIDASE; SULFURIC ACID; SYNAPTOTAGMIN I; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1 FLUORO 2,4 DINITROBENZENE; 2,4-DINITROFLUOROBENZENE SULFONIC ACID; PADGEM PROTEIN; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOODY DIARRHEA; COLON INJURY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENTEROCOLITIS; ENZYME ACTIVITY; EXPERIMENTAL COLITIS; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE EPITHELIUM CELL; LIPID PEROXIDATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TH1 CELL; UPREGULATION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CACO-2 CELL LINE; CHEMICALLY INDUCED; COLITIS; DISEASE MODEL; DRUG EFFECTS; KNOCKOUT MOUSE; PHYSIOLOGY;

ANIMALS; CACO-2 CELLS; COLITIS; DIMETHYL FUMARATE; DINITROFLUOROBENZENE; DISEASE MODELS, ANIMAL; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; MALE; MICE; MICE, KNOCKOUT; P-SELECTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84966351285     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv231     Document Type: Article

References (38)

1. Impellizzeri D, Bruschetta G, Di Paola R, et al. The anti-inflammatory and antioxidant effects of bergamot juice extract [BJE] in an experimental model of inflammatory bowel disease. Clin Nutr 2015;34:1146-54.
2. Cannarile L, Cuzzocrea S, Santucci L, et al. Glucocorticoid-induced leucine zipper is protective in th1-mediated models of colitis. Gastroenterology 2009;136:530-41.
3. Motomura Y, Wang H, Deng Y, et al. Helminth antigen-based strategy to ameliorate inflammation in an experimental model of colitis. Clin Exp Immunol 2009;155:88-95.
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-60.
5. Wilsmann-Theis D, Frambach Y, Philipp S, et al. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: Report on 17 cases. Dermatology 2015;230:119-27.
6. Miglio G, Veglia E, Fantozzi R. Fumaric acid esters prevent the nlrp3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated thp-1 cells. Int Immunopharmacol 2015;28:215-9.
7. Dubey D, Kieseier BC, Hartung HP, et al. Dimethyl fumarate in relapsingremitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015;15:339-46.
8. Duffy S, So A, Murphy TH. Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem 1998;71:69-77.
9. Wang Q, Chuikov S, Taitano S, et al. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through nrf2- erk1/2 mapk pathway. Int J Mol Sci 2015;16:13885-907.
10. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor [erythroid-derived 2]-like 2 pathway. J Pharmacol Exp Ther 2015;341:274-84.
11. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa b [nf-kappa b] in multiple myeloma: Downregulation of nf-kappa b induces apoptosis. Br J Haematol 2001;115:279-86.
12. Yamazoe Y, Tsubaki M, Matsuoka H, et al. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int 2009;33:1087-94.
13. Zhao G, Liu Y, Fang J, et al. Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1alpha [hif-1alpha]. Biochem Biophys Res Commun 2015;448:303-7.
14. Oh CJ, Park S, Kim JY, et al. Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and nrf2-dependent mechanisms. Redox Biol 2015;2:855-64.
15. Benardais K, Pul R, Singh V, et al. Effects of fumaric acid esters on bloodbrain barrier tight junction proteins. Neurosci Lett 2015;555:165-70.
16. Sturiale S, Barbara G, Qiu B, et al. Neutral endopeptidase [ec 3.4.24.11] terminates colitis by degrading substance p. Proc Natl Acad Sci U S A 1999;96:11653-8.
17. Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993;39:150-6.
18. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157-67.
19. Zhang J, Romero J, Chan A, et al. Biarylsulfonamide ccr9 inhibitors for inflammatory bowel disease. Bioorg Med Chem Lett 2015;25:3661-4.
20. Rieder F, Kessler S, Sans M, Fiocchi C. Animal models of intestinal fibrosis: New tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol 2015;303:G786-801.
21. Bickston SJ. Infliximab for ulcerative colitis induction of remission and maintenance therapy. Gastroenterol Hepatol 2007;3:55-6.
22. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92.
23. Dumitrescu G, Dahan K, Treton X, et al. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis. J Gastrointestin Liver Dis 2015;24:249-51.
24. Oh J, O'Connor PW. Established disease-modifying treatments in relapsing- remitting multiple sclerosis. Curr Opin Neurol 2015;28:220-9.
25. Miljkovic D, Blazevski J, Petkovic F, et al. A comparative analysis of multiple sclerosis-relevant anti-inflammatory properties of ethyl pyruvate and dimethyl fumarate. J Immunol 2015;194:2493-503.
26. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859-61.
27. Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: Therapeutic modulation via fumaric acid esters. Int J Mol Sci 2015;13:11783-803.
28. Mandalari G, Bisignano C, Genovese T, et al. Natural almond skin reduced oxidative stress and inflammation in an experimental model of inflammatory bowel disease. Int Immunopharmacol 2015;11:915-24.
29. Spehlmann ME, Eckmann L. Nuclear factor-kappa b in intestinal protection and destruction. Curr Opin Gastroenterol 2009;25:92-9.
30. Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappab [nfkappab] and extracellular signal-regulated kinase 1 and 2 [erk1/2] and mitogen stress-activated kinase 1 [msk1] signaling. J Biol Chem 2015;287:28017-26.
31. Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits tnfinduced nuclear entry of nf-kappa b/p65 in human endothelial cells. J Immunol 2002;168:4781-7.
32. Seidel P, Merfort I, Tamm M, Roth M. Inhibition of nf-kappab and ap-1 by dimethylfumarate correlates with down-regulated IL-6 secretion and proliferation in human lung fibroblasts. Swiss Med Wkly 2015;140:w13132.
33. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: A useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776-81.
34. Kawachi S, Jennings S, Panes J, et al. Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. Am J Physiol Gastrointest Liver Physiol 2000;278:G734-43.
35. Lu Y, Wahl LM. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/akt/ikkalpha/ nf-kappab pathway. J Leukoc Biol 2005;78:259-65.
36. Medina C, Radomski MW. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 2006;318:933-8.
37. Silosi I, Boldeanu MV, Mogoanta SS, et al. Matrix metalloproteinases [mmp-3 and mmp-9] implication in the pathogenesis of inflammatory bowel disease [IBD]. Rom J Morphol Embryol 2015;55: 1317-24.
38. Kunze R, Urrutia A, Hoffmann A, et al. Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity. Exp Neurol 2015;266:99-111.